Since the discovery of PTEN, this protein has been shown to be an effective suppressor of cancer and a contributor to longevity. This report will review, in depth, the associations between PTEN and other molecules, its mutations and regulations in order to present how PTEN can be used to increase longevity. This report will collect recent research of PTEN and use this to discuss PTEN’s role in caloric restriction, antioxidative defense of DNA-damage and the role it plays in suppressing tumors. The report will also discuss that variety of ways that PTEN can be compromised, through mutations, complete loss of alleles and its main antagonist, the PI3K/AKT pathway.
References
[1]
Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S.I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275, 1943–1947, doi:10.1126/science.275.5308.1943.
[2]
Steck, P.A.; Pershouse, M.A.; Jasser, S.A.; Yung, W.K.; Lin, H.; Ligon, A.H.; Langford, L.A.; Baumgard, M.L.; Hattier, T.; Davis, T.; et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15, 356–362, doi:10.1038/ng0497-356.
[3]
Ali, I.U.; Schriml, L.M.; Dean, M. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 1999, 91, 1922–1932, doi:10.1093/jnci/91.22.1922.
[4]
Ortega-Molina, A.; Efeyan, A.; Lopez-Guadamillas, E.; Munoz-Martin, M.; Gomez-Lopez, G.; Canamero, M.; Mulero, F.; Pastor, J.; Martinez, S.; Romanos, E.; et al. Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell. Metab. 2012, 15, 382–394, doi:10.1016/j.cmet.2012.02.001.
[5]
Sulis, M.L.; Parsons, R. PTEN: From pathology to biology. Trends Cell Biol. 2003, 13, 478–483, doi:10.1016/S0962-8924(03)00175-2.
[6]
Chen, H.; Rossier, C.; Morris, M.A.; Scott, H.S.; Gos, A.; Bairoch, A.; Antonarakis, S.E. A testis-specific gene, TPTE, encodes a putative transmembrane tyrosine phosphatase and maps to the pericentromeric region of human chromosomes 21 and 13, and to chromosomes 15, 22, and Y. Hum. Genet. 1999, 105, 399–409, doi:10.1007/s004390051122.
[7]
Wu, Y.; Dowbenko, D.; Pisabarro, M.T.; Dillard-Telm, L.; Koeppen, H.; Lasky, L.A. PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumor suppressor lipid phosphatase. J. Biol. Chem. 2001, 276, 21745–21753, doi:10.1074/jbc.M101480200.
[8]
Walker, S.M.; Downes, C.P.; Leslie, N.R. TPIP: A novel phosphoinositide 3-phosphatase. Biochem. J. 2001, 360, 277–283, doi:10.1042/0264-6021:3600277.
[9]
Lee, J.O.; Yang, H.; Georgescu, M.M.; di Cristofano, A.; Maehama, T.; Shi, Y.; Dixon, J.E.; Pandolfi, P.; Pavletich, N.P. Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99, 323–334, doi:10.1016/S0092-8674(00)81663-3.
[10]
Maehama, T.; Dixon, J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273, 13375–13378, doi:10.1074/jbc.273.22.13375.
[11]
Ashcroft, M.; Ludwig, R.L.; Woods, D.B.; Copeland, T.D.; Weber, H.O.; MacRae, E.J.; Vousden, K.H. Phosphorylation of HDM2 by Akt. Oncogene 2002, 21, 1955–1962, doi:10.1038/sj.onc.1205276.
[12]
Chang, C.J.; Mulholland, D.J.; Valamehr, B.; Mosessian, S.; Sellers, W.R.; Wu, H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol. Cell. Biol. 2008, 28, 3281–3289, doi:10.1128/MCB.00310-08.
Vazquez, F.; Ramaswamy, S.; Nakamura, N.; Sellers, W.R. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 2000, 20, 5010–5018, doi:10.1128/MCB.20.14.5010-5018.2000.
[22]
Leslie, N.R.; Downes, C.P. PTEN function: How normal cells control it and tumour cells lose it. Biochem. J. 2004, 382, 1–11, doi:10.1042/BJ20040825.
[23]
Vazquez, F.; Grossman, S.R.; Takahashi, Y.; Rokas, M.V.; Nakamura, N.; Sellers, W.R. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 2001, 276, 48627–48630, doi:10.1074/jbc.C100556200.
[24]
Pilarski, R.; Eng, C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J. Med. Genet. 2004, 41, 323–326, doi:10.1136/jmg.2004.018036.
[25]
Patel, L.; Pass, I.; Coxon, P.; Downes, C.P.; Smith, S.A.; Macphee, C.H. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr. Biol. 2001, 11, 764–768, doi:10.1016/S0960-9822(01)00225-1.
[26]
Dionisi, M.; Alexander, S.P.; Bennett, A.J. Oleamide activates peroxisome proliferator-activated receptor gamma (PPARgamma) in vitro. Lipids Health Dis. 2012, 11, 51, doi:10.1186/1476-511X-11-51.
[27]
Kim, H.J.; Ham, S.A.; Kim, M.Y.; Hwang, J.S.; Lee, H.; Kang, E.S.; Yoo, T.; Woo, I.S.; Yabe-Nishimura, C.; Paek, K.S.; et al. PPARdelta coordinates angiotensin II-induced senescence in vascular smooth muscle cells through PTEN-mediated inhibition of superoxide generation. J. Biol. Chem. 2011, 286, 44585–44593, doi:10.1074/jbc.M111.222562.
[28]
Virolle, T.; Adamson, E.D.; Baron, V.; Birle, D.; Mercola, D.; Mustelin, T.; de Belle, I. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat. Cell Biol. 2001, 3, 1124–1128, doi:10.1038/ncb1201-1124.
[29]
Sperandio, S.; Fortin, J.; Sasik, R.; Robitaille, L.; Corbeil, J.; de Belle, I. The transcription factor Egr1 regulates the HIF-1alpha gene during hypoxia. Mol. Carcinog. 2009, 48, 38–44, doi:10.1002/mc.20454.
[30]
Moorehead, R.A.; Hojilla, C.V.; de Belle, I.; Wood, G.A.; Fata, J.E.; Adamson, E.D.; Watson, K.L.; Edwards, D.R.; Khokha, R. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J. Biol. Chem. 2003, 278, 50422–50427, doi:10.1074/jbc.M306894200.
[31]
Codina, M.; Garcia de la serrana, D.; Sanchez-Gurmaches, J.; Montserrat, N.; Chistyakova, O.; Navarro, I.; Gutierrez, J. Metabolic and mitogenic effects of IGF-II in rainbow trout (Oncorhynchus mykiss) myocytes in culture and the role of IGF-II in the PI3K/Akt and MAPK signalling pathways. Gen. Comp. Endocrinol. 2008, 157, 116–124, doi:10.1016/j.ygcen.2008.04.009.
Hettinger, K.; Vikhanskaya, F.; Poh, M.K.; Lee, M.K.; de Belle, I.; Zhang, J.T.; Reddy, S.A.; Sabapathy, K. c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ. 2007, 14, 218–229, doi:10.1038/sj.cdd.4401946.
[34]
Vasudevan, K.M.; Gurumurthy, S.; Rangnekar, V.M. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol. Cell. Biol. 2004, 24, 1007–1021, doi:10.1128/MCB.24.3.1007-1021.2004.
[35]
Garcia, J.M.; Silva, J.; Pena, C.; Garcia, V.; Rodriguez, R.; Cruz, M.A.; Cantos, B.; Provencio, M.; Espana, P.; Bonilla, F. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004, 41, 117–124, doi:10.1002/gcc.20062.
[36]
Goel, A.; Arnold, C.N.; Niedzwiecki, D.; Carethers, J.M.; Dowell, J.M.; Wasserman, L.; Compton, C.; Mayer, R.J.; Bertagnolli, M.M.; Boland, C.R. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004, 64, 3014–3021, doi:10.1158/0008-5472.CAN-2401-2.
[37]
Kang, Y.H.; Lee, H.S.; Kim, W.H. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab. Invest. 2002, 82, 285–291.
[38]
Mirmohammadsadegh, A.; Marini, A.; Nambiar, S.; Hassan, M.; Tannapfel, A.; Ruzicka, T.; Hengge, U.R. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006, 66, 6546–6552, doi:10.1158/0008-5472.CAN-06-0384.
[39]
Zysman, M.A.; Chapman, W.B.; Bapat, B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am. J. Pathol. 2002, 160, 795–800, doi:10.1016/S0002-9440(10)64902-4.
[40]
Hamilton, J.A.; Stewart, L.M.; Ajayi, L.; Gray, I.C.; Gray, N.E.; Roberts, K.G.; Watson, G.J.; Kaisary, A.V.; Snary, D. The expression profile for the tumour suppressor gene PTEN and associated polymorphic markers. Br. J. Cancer 2000, 82, 1671–1676, doi:10.1054/bjoc.2000.1211.
[41]
Meng, F.; Henson, R.; Lang, M.; Wehbe, H.; Maheshwari, S.; Mendell, J.T.; Jiang, J.; Schmittgen, T.D.; Patel, T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130, 2113–2129, doi:10.1053/j.gastro.2006.02.057.
[42]
Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133, 647–658, doi:10.1053/j.gastro.2007.05.022.
[43]
Chan, J.A.; Krichevsky, A.M.; Kosik, K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65, 6029–6033, doi:10.1158/0008-5472.CAN-05-0137.
Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 2006, 103, 2257–2261, doi:10.1073/pnas.0510565103.
[46]
Okahara, F.; Ikawa, H.; Kanaho, Y.; Maehama, T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J. Biol. Chem. 2004, 279, 45300–45303, doi:10.1074/jbc.C400377200.
[47]
Georgescu, M.M.; Kirsch, K.H.; Akagi, T.; Shishido, T.; Hanafusa, H. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl. Acad. Sci. USA 1999, 96, 10182–10187, doi:10.1073/pnas.96.18.10182.
[48]
Torres, J.; Pulido, R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 2001, 276, 993–998, doi:10.1074/jbc.M009134200.
[49]
Maccario, H.; Perera, N.M.; Davidson, L.; Downes, C.P.; Leslie, N.R. PTEN is destabilized by phosphorylation on Thr366. Biochem. J. 2007, 405, 439–444, doi:10.1042/BJ20061837.
[50]
Martin, S.A.; Ouchi, T. Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN. Mol. Cancer Ther. 2008, 7, 2509–2516, doi:10.1158/1535-7163.MCT-08-0199.
[51]
Li, Z.; Dong, X.; Wang, Z.; Liu, W.; Deng, N.; Ding, Y.; Tang, L.; Hla, T.; Zeng, R.; Li, L.; et al. Regulation of PTEN by Rho small GTPases. Nat. Cell Biol. 2005, 7, 399–404, doi:10.1038/ncb1236.
[52]
Al-Khouri, A.M.; Ma, Y.; Togo, S.H.; Williams, S.; Mustelin, T. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J. Biol. Chem. 2005, 280, 35195–35202, doi:10.1074/jbc.M503045200.
[53]
Miller, S.J.; Lou, D.Y.; Seldin, D.C.; Lane, W.S.; Neel, B.G. Direct identification of PTEN phosphorylation sites. FEBS Lett. 2002, 528, 145–153, doi:10.1016/S0014-5793(02)03274-X.
[54]
Wu, W.; Wang, X.; Zhang, W.; Reed, W.; Samet, J.M.; Whang, Y.E.; Ghio, A.J. Zinc-induced PTEN protein degradation through the proteasome pathway in human airway epithelial cells. J. Biol. Chem. 2003, 278, 28258–28263, doi:10.1074/jbc.M303318200.
[55]
Tang, Y.; Eng, C. p53 Down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Res. 2006, 66, 6139–6148, doi:10.1158/0008-5472.CAN-06-0772.
[56]
Wang, X.; Trotman, L.C.; Koppie, T.; Alimonti, A.; Chen, Z.; Gao, Z.; Wang, J.; Erdjument-Bromage, H.; Tempst, P.; Cordon-Cardo, C.; et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007, 128, 129–139, doi:10.1016/j.cell.2006.11.039.
Lee, S.R.; Yang, K.S.; Kwon, J.; Lee, C.; Jeong, W.; Rhee, S.G. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 2002, 277, 20336–20342, doi:10.1074/jbc.M111899200.
[59]
Kwon, J.; Lee, S.R.; Yang, K.S.; Ahn, Y.; Kim, Y.J.; Stadtman, E.R.; Rhee, S.G. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. USA 2004, 101, 16419–16424, doi:10.1073/pnas.0407396101.
[60]
Leslie, N.R.; Bennett, D.; Lindsay, Y.E.; Stewart, H.; Gray, A.; Downes, C.P. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 2003, 22, 5501–5510, doi:10.1093/emboj/cdg513.
[61]
Wu, X.; Hepner, K.; Castelino-Prabhu, S.; Do, D.; Kaye, M.B.; Yuan, X.J.; Wood, J.; Ross, C.; Sawyers, C.L.; Whang, Y.E. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl. Acad. Sci. USA 2000, 97, 4233–4238, doi:10.1073/pnas.97.8.4233.
[62]
Takahashi, Y.; Morales, F.C.; Kreimann, E.L.; Georgescu, M.M. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J. 2006, 25, 910–920, doi:10.1038/sj.emboj.7600979.
[63]
Xia, D.; Srinivas, H.; Ahn, Y.H.; Sethi, G.; Sheng, X.; Yung, W.K.; Xia, Q.; Chiao, P.J.; Kim, H.; Brown, P.H.; et al. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J. Biol. Chem. 2007, 282, 3507–3519.
[64]
Stambolic, V.; Suzuki, A.; de la Pompa, J.L.; Brothers, G.M.; Mirtsos, C.; Sasaki, T.; Ruland, J.; Penninger, J.M.; Siderovski, D.P.; Mak, T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95, 29–39, doi:10.1016/S0092-8674(00)81780-8.
[65]
Vivanco, I.; Palaskas, N.; Tran, C.; Finn, S.P.; Getz, G.; Kennedy, N.J.; Jiao, J.; Rose, J.; Xie, W.; Loda, M.; et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007, 11, 555–569, doi:10.1016/j.ccr.2007.04.021.
Freeman, D.J.; Li, A.G.; Wei, G.; Li, H.H.; Kertesz, N.; Lesche, R.; Whale, A.D.; Martinez-Diaz, H.; Rozengurt, N.; Cardiff, R.D.; et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003, 3, 117–130, doi:10.1016/S1535-6108(03)00021-7.
[68]
Chen, Z.; Trotman, L.C.; Shaffer, D.; Lin, H.K.; Dotan, Z.A.; Niki, M.; Koutcher, J.A.; Scher, H.I.; Ludwig, T.; Gerald, W.; et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436, 725–730, doi:10.1038/nature03918.
[69]
Alimonti, A.; Nardella, C.; Chen, Z.; Clohessy, J.G.; Carracedo, A.; Trotman, L.C.; Cheng, K.; Varmeh, S.; Kozma, S.C.; Thomas, G.; et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Investig. 2010, 120, 681–693, doi:10.1172/JCI40535.
[70]
Li, A.G.; Piluso, L.G.; Cai, X.; Wei, G.; Sellers, W.R.; Liu, X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol. Cell 2006, 23, 575–587, doi:10.1016/j.molcel.2006.06.028.
[71]
Puc, J.; Parsons, R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 2005, 4, 927–929, doi:10.4161/cc.4.7.1795.
[72]
Shen, W.H.; Balajee, A.S.; Wang, J.; Wu, H.; Eng, C.; Pandolfi, P.P.; Yin, Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128, 157–170, doi:10.1016/j.cell.2006.11.042.
Salminen, A.; Ojala, J.; Huuskonen, J.; Kauppinen, A.; Suuronen, T.; Kaarniranta, K. Interaction of aging-associated signaling cascades: Inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell. Mol. Life Sci. 2008, 65, 1049–1058, doi:10.1007/s00018-008-7461-3.
[76]
Salminen, A.; Kaarniranta, K. NF-kappaB signaling in the aging process. J. Clin. Immunol. 2009, 29, 397–405, doi:10.1007/s10875-009-9296-6.
[77]
Carracedo, A.; Pandolfi, P.P. The PTEN-PI3K pathway: Of feedbacks and cross-talks. Oncogene 2008, 27, 5527–5541, doi:10.1038/onc.2008.247.
[78]
Scanga, S.E.; Ruel, L.; Binari, R.C.; Snow, B.; Stambolic, V.; Bouchard, D.; Peters, M.; Calvieri, B.; Mak, T.W.; Woodgett, J.R.; et al. The conserved PI3'K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila. Oncogene 2000, 19, 3971–3977, doi:10.1038/sj.onc.1203739.
[79]
Wang, Y. Bulky DNA lesions induced by reactive oxygen species. Chem. Res. Toxicol. 2008, 21, 276–281, doi:10.1021/tx700411g.
[80]
Chalhoub, N.; Baker, S.J. PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4, 127–150, doi:10.1146/annurev.pathol.4.110807.092311.
[81]
Backman, S.A.; Stambolic, V.; Suzuki, A.; Haight, J.; Elia, A.; Pretorius, J.; Tsao, M.S.; Shannon, P.; Bolon, B.; Ivy, G.O.; et al. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 2001, 29, 396–403.
[82]
Cho, K.S.; Lee, J.H.; Kim, S.; Kim, D.; Koh, H.; Lee, J.; Kim, C.; Kim, J.; Chung, J. Drosophila phosphoinositide-dependent kinase-1 regulates apoptosis and growth via the phosphoinositide 3-kinase-dependent signaling pathway. Proc. Natl. Acad. Sci. USA 2001, 98, 6144–6149, doi:10.1073/pnas.101596998.
[83]
Alessi, D.R.; Andjelkovic, M.; Caudwell, B.; Cron, P.; Morrice, N.; Cohen, P.; Hemmings, B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15, 6541–6551.
[84]
Brognard, J.; Sierecki, E.; Gao, T.; Newton, A.C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 2007, 25, 917–931, doi:10.1016/j.molcel.2007.02.017.
[85]
Gao, T.; Furnari, F.; Newton, A.C. PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 2005, 18, 13–24, doi:10.1016/j.molcel.2005.03.008.
Guertin, D.A.; Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12, 9–22, doi:10.1016/j.ccr.2007.05.008.
[88]
Manning, B.D. Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 2004, 167, 399–403, doi:10.1083/jcb.200408161.
[89]
Puig, O.; Tjian, R. Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Dev. 2005, 19, 2435–2446, doi:10.1101/gad.1340505.
[90]
Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91, 231–241, doi:10.1016/S0092-8674(00)80405-5.
[91]
Cardone, M.H.; Roy, N.; Stennicke, H.R.; Salvesen, G.S.; Franke, T.F.; Stanbridge, E.; Frisch, S.; Reed, J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282, 1318–1321, doi:10.1126/science.282.5392.1318.
Mayo, L.D.; Donner, D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 2001, 98, 11598–11603, doi:10.1073/pnas.181181198.
[94]
Calnan, D.R.; Brunet, A. The FoxO code. Oncogene 2008, 27, 2276–2288, doi:10.1038/onc.2008.21.
[95]
Van Der Heide, L.P.; Hoekman, M.F.; Smidt, M.P. The ins and outs of FoxO shuttling: Mechanisms of FoxO translocation and transcriptional regulation. Biochem. J. 2004, 380, 297–309, doi:10.1042/BJ20040167.
Van der Horst, A.; Burgering, B.M. Stressing the role of FoxO proteins in lifespan and disease. Nat. Rev. Mol. Cell Biol. 2007, 8, 440–450, doi:10.1038/nrm2190.
[98]
Peng, S.L. Foxo in the immune system. Oncogene 2008, 27, 2337–2344, doi:10.1038/onc.2008.26.
[99]
Das, S.; Dixon, J.E.; Cho, W. Membrane-binding and activation mechanism of PTEN. Proc. Natl. Acad. Sci. USA 2003, 100, 7491–7496, doi:10.1073/pnas.0932835100.
[100]
Deichmann, M.; Thome, M.; Benner, A.; Egner, U.; Hartschuh, W.; Naher, H. PTEN/MMAC1 expression in melanoma resection specimens. Br. J. Cancer 2002, 87, 1431–1436, doi:10.1038/sj.bjc.6600653.
[101]
McMenamin, M.E.; Soung, P.; Perera, S.; Kaplan, I.; Loda, M.; Sellers, W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59, 4291–4296.
[102]
Lachyankar, M.B.; Condon, P.J.; Daou, M.C.; de, A.K.; Levine, J.B.; Obermeier, A.; Ross, A.H. Novel functional interactions between Trk kinase and p75 neurotrophin receptor in neuroblastoma cells. J. Neurosci. Res. 2003, 71, 157–172, doi:10.1002/jnr.10480.
[103]
Sano, T.; Lin, H.; Chen, X.; Langford, L.A.; Koul, D.; Bondy, M.L.; Hess, K.R.; Myers, J.N.; Hong, Y.K.; Yung, W.K.; et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: Relationship to localization and prognosis. Cancer Res. 1999, 59, 1820–1824.
[104]
Gimm, O.; Perren, A.; Weng, L.P.; Marsh, D.J.; Yeh, J.J.; Ziebold, U.; Gil, E.; Hinze, R.; Delbridge, L.; Lees, J.A.; et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol. 2000, 156, 1693–1700, doi:10.1016/S0002-9440(10)65040-7.
[105]
Tamura, M.; Gu, J.; Matsumoto, K.; Aota, S.; Parsons, R.; Yamada, K.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998, 280, 1614–1617, doi:10.1126/science.280.5369.1614.
[106]
Liliental, J.; Moon, S.Y.; Lesche, R.; Mamillapalli, R.; Li, D.; Zheng, Y.; Sun, H.; Wu, H. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr. Biol. 2000, 10, 401–404, doi:10.1016/S0960-9822(00)00417-6.
[107]
Raftopoulou, M.; Etienne-Manneville, S.; Self, A.; Nicholls, S.; Hall, A. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 2004, 303, 1179–1181, doi:10.1126/science.1092089.
[108]
Li, D.M.; Sun, H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997, 57, 2124–2129.
[109]
Whang, Y.E.; Wu, X.; Suzuki, H.; Reiter, R.E.; Tran, C.; Vessella, R.L.; Said, J.W.; Isaacs, W.B.; Sawyers, C.L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 1998, 95, 5246–5250, doi:10.1073/pnas.95.9.5246.
[110]
Lian, Z.; di Cristofano, A. Class reunion: PTEN joins the nuclear crew. Oncogene 2005, 24, 7394–7400, doi:10.1038/sj.onc.1209089.
[111]
Lachyankar, M.B.; Sultana, N.; Schonhoff, C.M.; Mitra, P.; Poluha, W.; Lambert, S.; Quesenberry, P.J.; Litofsky, N.S.; Recht, L.D.; Nabi, R.; et al. A role for nuclear PTEN in neuronal differentiation. J. Neurosci. 2000, 20, 1404–1413.
[112]
Perren, A.; Komminoth, P.; Saremaslani, P.; Matter, C.; Feurer, S.; Lees, J.A.; Heitz, P.U.; Eng, C. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. J. Pathol. 2000, 157, 1097–1103.
[113]
Deleris, P.; Bacqueville, D.; Gayral, S.; Carrez, L.; Salles, J.P.; Perret, B.; Breton-Douillon, M. SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles. J. Biol. Chem. 2003, 278, 38884–38891, doi:10.1074/jbc.M300816200.
[114]
Ginn-Pease, M.E.; Eng, C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0–G1 in MCF-7 cells. Cancer Res. 2003, 63, 282–286.
[115]
Perren, A.; Weng, L.P.; Boag, A.H.; Ziebold, U.; Thakore, K.; Dahia, P.L.; Komminoth, P.; Lees, J.A.; Mulligan, L.M.; Mutter, G.L.; et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 1999, 155, 1253–1260.
[116]
Planchon, S.M.; Waite, K.A.; Eng, C. The nuclear affairs of PTEN. J. Cell Sci. 2008, 121, 249–253, doi:10.1242/jcs.022459.
[117]
Chung, J.H.; Ginn-Pease, M.E.; Eng, C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res. 2005, 65, 4108–4116, doi:10.1158/0008-5472.CAN-05-0124.
[118]
Liu, J.L.; Mao, Z.; LaFortune, T.A.; Alonso, M.M.; Gallick, G.E.; Fueyo, J.; Yung, W.K. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res. 2007, 67, 11054–11063, doi:10.1158/0008-5472.CAN-07-1263.
[119]
Gil, A.; Andres-Pons, A.; Fernandez, E.; Valiente, M.; Torres, J.; Cervera, J.; Pulido, R. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol. Biol. Cell 2006, 17, 4002–4013, doi:10.1091/mbc.E06-05-0380.
[120]
Radu, A.; Neubauer, V.; Akagi, T.; Hanafusa, H.; Georgescu, M.M. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol. Cell. Biol. 2003, 23, 6139–6149, doi:10.1128/MCB.23.17.6139-6149.2003.
[121]
Van Gent, D.C.; Hoeijmakers, J.H.; Kanaar, R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet. 2001, 2, 196–206.
[122]
Cleveland, D.W.; Mao, Y.; Sullivan, K.F. Centromeres and kinetochores: From epigenetics to mitotic checkpoint signaling. Cell 2003, 112, 407–421, doi:10.1016/S0092-8674(03)00115-6.
[123]
Lindsay, Y.; McCoull, D.; Davidson, L.; Leslie, N.R.; Fairservice, A.; Gray, A.; Lucocq, J.; Downes, C.P. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J. Cell Sci. 2006, 119, 5160–5168, doi:10.1242/jcs.000133.
[124]
Matheu, A.; Maraver, A.; Klatt, P.; Flores, I.; Garcia-Cao, I.; Borras, C.; Flores, J.M.; Vina, J.; Blasco, M.A.; Serrano, M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007, 448, 375–379, doi:10.1038/nature05949.
[125]
Wang, C.; Jurk, D.; Maddick, M.; Nelson, G.; Martin-Ruiz, C.; von Zglinicki, T. DNA damage response and cellular senescence in tissues of aging mice. Aging cell 2009, 8, 311–323, doi:10.1111/j.1474-9726.2009.00481.x.
Friedberg, E.C. DNA damage and repair. Nature 2003, 421, 436–440, doi:10.1038/nature01408.
[128]
Cline, S.D.; Hanawalt, P.C. Who’s on first in the cellular response to DNA damage? Nat. Rev. Mol. Cell Biol. 2003, 4, 361–372, doi:10.1038/nrm1101.
[129]
Branzei, D.; Foiani, M. Regulation of DNA repair throughout the cell cycle. Nat. Rev. Mol. Cell Biol. 2008, 9, 297–308, doi:10.1038/nrm2351.
[130]
Seviour, E.G.; Lin, S.Y. The DNA damage response: Balancing the scale between cancer and ageing. Aging 2010, 2, 900–907.
[131]
Cleaver, J.E. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat. Rev. Cancer 2005, 5, 564–573, doi:10.1038/nrc1652.
[132]
Cleaver, J.E.; Lam, E.T.; Revet, I. Disorders of nucleotide excision repair: The genetic and molecular basis of heterogeneity. Nat. Revs. Genet. 2009, 10, 756–768, doi:10.1038/nrg2663.
[133]
Sugasawa, K. UV-induced ubiquitylation of XPC complex, the UV-DDB-ubiquitin ligase complex, and DNA repair. J. Mol. Histol. 2006, 37, 189–202, doi:10.1007/s10735-006-9044-7.
[134]
Sugasawa, K.; Ng, J.M.; Masutani, C.; Iwai, S.; van der Spek, P.J.; Eker, A.P.; Hanaoka, F.; Bootsma, D.; Hoeijmakers, J.H. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol. Cell 1998, 2, 223–232, doi:10.1016/S1097-2765(00)80132-X.
[135]
Niggli, H.J.; Rothlisberger, R. Cyclobutane-type pyrimidine photodimer formation and induction of ornithine decarboxylase in human skin fibroblasts after UV irradiation. J. Investig. Dermatol. 1988, 91, 579–584.
[136]
Vink, A.A.; Berg, R.J.; de Gruijl, F.R.; Roza, L.; Baan, R.A. Induction, repair and accumulation of thymine dimers in the skin of UV-B-irradiated hairless mice. Carcinogenesis 1991, 12, 861–864, doi:10.1093/carcin/12.5.861.
[137]
Cimprich, K.A.; Cortez, D. ATR: An essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 2008, 9, 616–627, doi:10.1038/nrm2450.
[138]
Ming, M.; Shea, C.R.; Guo, X.; Li, X.; Soltani, K.; Han, W.; He, Y.Y. Regulation of global genome nucleotide excision repair by SIRT1 through xeroderma pigmentosum C. Proc. Natl. Acad. Sci. USA 2010, 107, 22623–22628.
[139]
Gupta, A.; Yang, Q.; Pandita, R.K.; Hunt, C.R.; Xiang, T.; Misri, S.; Zeng, S.; Pagan, J.; Jeffery, J.; Puc, J.; et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009, 8, 2198–2210, doi:10.4161/cc.8.14.8947.
[140]
Brown, E.J.; Baltimore, D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 2003, 17, 615–628, doi:10.1101/gad.1067403.
[141]
Chehab, N.H.; Malikzay, A.; Appel, M.; Halazonetis, T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 2000, 14, 278–288.
[142]
Yoon, K.; Smart, R.C. C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol. Cell. Biol. 2004, 24, 10650–10660, doi:10.1128/MCB.24.24.10650-10660.2004.
[143]
Groszer, M.; Erickson, R.; Scripture-Adams, D.D.; Lesche, R.; Trumpp, A.; Zack, J.A.; Kornblum, H.I.; Liu, X.; Wu, H. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001, 294, 2186–2189, doi:10.1126/science.1065518.
Wan, X.; Li, J.; Xie, X.; Lu, W. PTEN augments doxorubicin-induced apoptosis in PTEN-null Ishikawa cells. Int. J. Gynecol. Cancer 2007, 17, 808–812, doi:10.1111/j.1525-1438.2007.00890.x.
[148]
Flores, E.R.; Tsai, K.Y.; Crowley, D.; Sengupta, S.; Yang, A.; McKeon, F.; Jacks, T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002, 416, 560–564, doi:10.1038/416560a.
[149]
Lehman, J.A.; Waning, D.L.; Batuello, C.N.; Cipriano, R.; Kadakia, M.P.; Mayo, L.D. Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress. J. Biol. Chem. 2011, 286, 36631–36640, doi:10.1074/jbc.M110.217620.
Um, S.H.; Frigerio, F.; Watanabe, M.; Picard, F.; Joaquin, M.; Sticker, M.; Fumagalli, S.; Allegrini, P.R.; Kozma, S.C.; Auwerx, J.; et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004, 431, 200–205, doi:10.1038/nature02866.
[157]
Um, S.H.; D’Alessio, D.; Thomas, G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006, 3, 393–402, doi:10.1016/j.cmet.2006.05.003.
[158]
Mehta, L.H.; Roth, G.S. Caloric restriction and longevity: The science and the ascetic experience. Ann. N. Y. Acad. Sci. 2009, 1172, 28–33.
[159]
Fontana, L.; Partridge, L.; Longo, V.D. Extending healthy life span—From yeast to humans. Science 2010, 328, 321–326, doi:10.1126/science.1172539.
[160]
Dorman, J.B.; Albinder, B.; Shroyer, T.; Kenyon, C. The age-1 and daf-2 genes function in a common pathway to control the lifespan of Caenorhabditis elegans. Genetics 1995, 141, 1399–1406.
[161]
Masse, I.; Molin, L.; Billaud, M.; Solari, F. Lifespan and dauer regulation by tissue-specific activities of Caenorhabditis elegans DAF-18. Dev. Biol. 2005, 286, 91–101, doi:10.1016/j.ydbio.2005.07.010.
[162]
Morris, J.Z.; Tissenbaum, H.A.; Ruvkun, G. A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 1996, 382, 536–539, doi:10.1038/382536a0.
[163]
Hempenstall, S.; Picchio, L.; Mitchell, S.E.; Speakman, J.R.; Selman, C. The impact of acute caloric restriction on the metabolic phenotype in male C57BL/6 and DBA/2 mice. Mech. Ageing Dev. 2010, 131, 111–118, doi:10.1016/j.mad.2009.12.008.
[164]
Jiang, H.; Schiffer, E.; Song, Z.; Wang, J.; Zurbig, P.; Thedieck, K.; Moes, S.; Bantel, H.; Saal, N.; Jantos, J.; et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc. Natl. Acad. Sci. USA 2008, 105, 11299–11304, doi:10.1073/pnas.0801457105.
[165]
Moore, T.; Beltran, L.; Carbajal, S.; Strom, S.; Traag, J.; Hursting, S.D.; di Giovanni, J. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev. Res. 2008, 1, 65–76, doi:10.1158/1940-6207.CAPR-08-0022.
[166]
Kozak, L.P.; Anunciado-Koza, R. UCP1: Its involvement and utility in obesity. Int. J. Obes. 2008, 32, S32–S38, doi:10.1038/ijo.2008.236.
[167]
Nedergaard, J.; Cannon, B. The changed metabolic world with human brown adipose tissue: Therapeutic visions. Cell Metab. 2010, 11, 268–272, doi:10.1016/j.cmet.2010.03.007.
[168]
Risinger, J.I.; Hayes, A.K.; Berchuck, A.; Barrett, J.C. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997, 57, 4736–4738.
[169]
Tashiro, H.; Blazes, M.S.; Wu, R.; Cho, K.R.; Bose, S.; Wang, S.I.; Li, J.; Parsons, R.; Ellenson, L.H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997, 57, 3935–3940.
[170]
Saal, L.H.; Gruvberger-Saal, S.K.; Persson, C.; Lovgren, K.; Jumppanen, M.; Staaf, J.; Jonsson, G.; Pires, M.M.; Maurer, M.; Holm, K.; et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet. 2008, 40, 102–107, doi:10.1038/ng.2007.39.
[171]
Cantley, L.C.; Neel, B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA 1999, 96, 4240–4245, doi:10.1073/pnas.96.8.4240.
[172]
Suzuki, A.; Yamaguchi, M.T.; Ohteki, T.; Sasaki, T.; Kaisho, T.; Kimura, Y.; Yoshida, R.; Wakeham, A.; Higuchi, T.; Fukumoto, M.; et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001, 14, 523–534, doi:10.1016/S1074-7613(01)00134-0.
[173]
Crackower, M.A.; Oudit, G.Y.; Kozieradzki, I.; Sarao, R.; Sun, H.; Sasaki, T.; Hirsch, E.; Suzuki, A.; Shioi, T.; Irie-Sasaki, J.; et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002, 110, 737–749, doi:10.1016/S0092-8674(02)00969-8.
[174]
Kimura, T.; Suzuki, A.; Fujita, Y.; Yomogida, K.; Lomeli, H.; Asada, N.; Ikeuchi, M.; Nagy, A.; Mak, T.W.; Nakano, T. Conditional loss of PTEN leads to testicular teratoma and enhances embryonic germ cell production. Development 2003, 130, 1691–1700, doi:10.1242/dev.00392.
[175]
Podsypanina, K.; Ellenson, L.H.; Nemes, A.; Gu, J.; Tamura, M.; Yamada, K.M.; Cordon-Cardo, C.; Catoretti, G.; Fisher, P.E.; Parsons, R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA 1999, 96, 1563–1568, doi:10.1073/pnas.96.4.1563.
[176]
Di Cristofano, A.; Kotsi, P.; Peng, Y.F.; Cordon-Cardo, C.; Elkon, K.B.; Pandolfi, P.P. Impaired Fas response and autoimmunity in Pten+/？ mice. Science 1999, 285, 2122–2125, doi:10.1126/science.285.5436.2122.
[177]
Di Cristofano, A.; de Acetis, M.; Koff, A.; Cordon-Cardo, C.; Pandolfi, P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 2001, 27, 222–224, doi:10.1038/84879.
[178]
Dahia, P.L. PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer 2000, 7, 115–129, doi:10.1677/erc.0.0070115.
[179]
Marsh, D.J.; Kum, J.B.; Lunetta, K.L.; Bennett, M.J.; Gorlin, R.J.; Ahmed, S.F.; Bodurtha, J.; Crowe, C.; Curtis, M.A.; Dasouki, M.; et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum. Mol. Genet. 1999, 8, 1461–1472, doi:10.1093/hmg/8.8.1461.
[180]
Rustad, C.F.; Bjornslett, M.; Heimdal, K.R.; Maehle, L.; Apold, J.; Moller, P. Germline PTEN mutations are rare and highly penetrant. Hered. Cancer Clin. Pract. 2006, 4, 177–185, doi:10.1186/1897-4287-4-4-177.
[181]
Liaw, D.; Marsh, D.J.; Li, J.; Dahia, P.L.; Wang, S.I.; Zheng, Z.; Bose, S.; Call, K.M.; Tsou, H.C.; Peacocke, M.; et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16, 64–67, doi:10.1038/ng0597-64.
[182]
Marsh, D.J.; Dahia, P.L.; Zheng, Z.; Liaw, D.; Parsons, R.; Gorlin, R.J.; Eng, C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat. Genet. 1997, 16, 333–334, doi:10.1038/ng0897-333.
[183]
Suzuki, A.; de la Pompa, J.L.; Stambolic, V.; Elia, A.J.; Sasaki, T.; del Barco Barrantes, I.; Ho, A.; Wakeham, A.; Itie, A.; Khoo, W.; et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 1998, 8, 1169–1178, doi:10.1016/S0960-9822(07)00488-5.
[184]
Blumenthal, G.M.; Dennis, P.A. PTEN hamartoma tumor syndromes. Eur. J. Human Genet. 2008, 16, 1289–1300, doi:10.1038/ejhg.2008.162.
[185]
Backman, S.A.; Ghazarian, D.; So, K.; Sanchez, O.; Wagner, K.U.; Hennighausen, L.; Suzuki, A.; Tsao, M.S.; Chapman, W.B.; Stambolic, V.; et al. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc. Natl. Acad. Sci. USA 2004, 101, 1725–1730, doi:10.1073/pnas.0308217100.
[186]
Li, G.; Robinson, G.W.; Lesche, R.; Martinez-Diaz, H.; Jiang, Z.; Rozengurt, N.; Wagner, K.U.; Wu, D.C.; Lane, T.F.; Liu, X.; et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002, 129, 4159–4170.
[187]
Suzuki, G. Characterization of TP53, APC, and PTEN mutational statuses of 120 human cancer cell lines by using yeast-based analyses. Hokkaido Igaku Zasshi 2003, 78, 437–449.
[188]
Yanagi, S.; Kishimoto, H.; Kawahara, K.; Sasaki, T.; Sasaki, M.; Nishio, M.; Yajima, N.; Hamada, K.; Horie, Y.; Kubo, H.; et al. Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. J. Clin. Investig. 2007, 117, 2929–2940, doi:10.1172/JCI31854.
[189]
Busa, T.; Chabrol, B.; Perret, O.; Longy, M.; Philip, N. Novel PTEN germline mutation in a family with mild phenotype: Difficulties in genetic counseling. Gene 2013, 512, 194–197, doi:10.1016/j.gene.2012.09.134.
[190]
McBride, K.L.; Varga, E.A.; Pastore, M.T.; Prior, T.W.; Manickam, K.; Atkin, J.F.; Herman, G.E. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. Autism Res. 2010, 3, 137–141, doi:10.1002/aur.132.
[191]
Simpson, L.; Parsons, R. PTEN: Life as a tumor suppressor. Exp. Cell Res. 2001, 264, 29–41, doi:10.1006/excr.2000.5130.
[192]
Oldham, S.; Stocker, H.; Laffargue, M.; Wittwer, F.; Wymann, M.; Hafen, E. The Drosophila insulin/IGF receptor controls growth and size by modulating PtdInsP(3) levels. Development 2002, 129, 4103–4109.
[193]
Gao, X.; Neufeld, T.P.; Pan, D. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. Dev. Biol. 2000, 221, 404–418, doi:10.1006/dbio.2000.9680.
[194]
Whiteman, D.C.; Zhou, X.P.; Cummings, M.C.; Pavey, S.; Hayward, N.K.; Eng, C. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int. J. Cancer 2002, 99, 63–67, doi:10.1002/ijc.10294.
[195]
Zhou, X.P.; Gimm, O.; Hampel, H.; Niemann, T.; Walker, M.J.; Eng, C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am. J. Pathol. 2000, 157, 1123–1128, doi:10.1016/S0002-9440(10)64627-5.
[196]
Fridberg, M.; Servin, A.; Anagnostaki, L.; Linderoth, J.; Berglund, M.; Soderberg, O.; Enblad, G.; Rosen, A.; Mustelin, T.; Jerkeman, M.; et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk. Lymphoma 2007, 48, 2221–2232, doi:10.1080/10428190701636443.
[197]
Zhou, X.P.; Loukola, A.; Salovaara, R.; Nystrom-Lahti, M.; Peltomaki, P.; de la Chapelle, A.; Aaltonen, L.A.; Eng, C. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am. J. Pathol. 2002, 161, 439–447, doi:10.1016/S0002-9440(10)64200-9.
[198]
Tachibana, M.; Shibakita, M.; Ohno, S.; Kinugasa, S.; Yoshimura, H.; Ueda, S.; Fujii, T.; Rahman, M.A.; Dhar, D.K.; Nagasue, N. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 2002, 94, 1955–1960, doi:10.1002/cncr.0678.
[199]
Liu, Y.; Majumder, S.; McCall, W.; Sartor, C.I.; Mohler, J.L.; Gregory, C.W.; Earp, H.S.; Whang, Y.E. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res. 2005, 65, 3404–3409.
[200]
Okumura, K.; Zhao, M.; DePinho, R.A.; Furnari, F.B.; Cavenee, W.K. PTEN: A novel anti-oncogenic function independent of phosphatase activity. Cell Cycle 2005, 4, 540–542, doi:10.4161/cc.4.4.1614.
[201]
Okumura, K.; Zhao, M.; Depinho, R.A.; Furnari, F.B.; Cavenee, W.K. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc. Natl. Acad. Sci. USA 2005, 102, 2703–2706, doi:10.1073/pnas.0409370102.
[202]
Soria, J.C.; Lee, H.Y.; Lee, J.I.; Wang, L.; Issa, J.P.; Kemp, B.L.; Liu, D.D.; Kurie, J.M.; Mao, L.; Khuri, F.R. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 2002, 8, 1178–1184.
[203]
Vasudevan, K.M.; Burikhanov, R.; Goswami, A.; Rangnekar, V.M. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res. 2007, 67, 10343–10350, doi:10.1158/0008-5472.CAN-07-1827.
